Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.19
SPNC's Cash to Debt is ranked lower than
87% of the 326 Companies
in the Global Medical Devices industry.

( Industry Median: 2.32 vs. SPNC: 0.19 )
Ranked among companies with meaningful Cash to Debt only.
SPNC' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: No Debt Max: No Debt
Current: 0.19
Equity to Asset 0.19
SPNC's Equity to Asset is ranked lower than
89% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. SPNC: 0.19 )
Ranked among companies with meaningful Equity to Asset only.
SPNC' s Equity to Asset Range Over the Past 10 Years
Min: 0.19  Med: 0.71 Max: 0.89
Current: 0.19
0.19
0.89
F-Score: 5
Z-Score: 1.34
M-Score: -2.75
WACC vs ROIC
10.11%
-12.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -16.17
SPNC's Operating margin (%) is ranked lower than
64% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. SPNC: -16.17 )
Ranked among companies with meaningful Operating margin (%) only.
SPNC' s Operating margin (%) Range Over the Past 10 Years
Min: -20.54  Med: -5.51 Max: 2.1
Current: -16.17
-20.54
2.1
Net-margin (%) -21.19
SPNC's Net-margin (%) is ranked lower than
66% of the 308 Companies
in the Global Medical Devices industry.

( Industry Median: 1.87 vs. SPNC: -21.19 )
Ranked among companies with meaningful Net-margin (%) only.
SPNC' s Net-margin (%) Range Over the Past 10 Years
Min: -24.18  Med: -3.04 Max: 8.72
Current: -21.19
-24.18
8.72
ROE (%) -53.68
SPNC's ROE (%) is ranked lower than
79% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.47 vs. SPNC: -53.68 )
Ranked among companies with meaningful ROE (%) only.
SPNC' s ROE (%) Range Over the Past 10 Years
Min: -53.68  Med: -3.54 Max: 8.5
Current: -53.68
-53.68
8.5
ROA (%) -12.57
SPNC's ROA (%) is ranked lower than
61% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. SPNC: -12.57 )
Ranked among companies with meaningful ROA (%) only.
SPNC' s ROA (%) Range Over the Past 10 Years
Min: -13.44  Med: -2.95 Max: 7.25
Current: -12.57
-13.44
7.25
ROC (Joel Greenblatt) (%) -54.13
SPNC's ROC (Joel Greenblatt) (%) is ranked lower than
63% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 3.44 vs. SPNC: -54.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SPNC' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -68.16  Med: -16.73 Max: 8.73
Current: -54.13
-68.16
8.73
Revenue Growth (3Y)(%) 13.90
SPNC's Revenue Growth (3Y)(%) is ranked higher than
80% of the 233 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. SPNC: 13.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SPNC' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -4  Med: 8.6 Max: 29.3
Current: 13.9
-4
29.3
» SPNC's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SPNC Guru Trades in Q4 2015

Ron Baron 1,794,488 sh (-15.37%)
Steven Cohen 594,900 sh (-21.07%)
» More
Q1 2016

SPNC Guru Trades in Q1 2016

Steven Cohen Sold Out
Ron Baron 1,772,488 sh (-1.23%)
» More
Q2 2016

SPNC Guru Trades in Q2 2016

Steven Cohen 276,800 sh (New)
Ron Baron 1,772,488 sh (unchged)
» More
Q3 2016

SPNC Guru Trades in Q3 2016

Paul Tudor Jones 14,550 sh (New)
Jim Simons 32,222 sh (New)
Ron Baron 1,528,500 sh (-13.77%)
Steven Cohen 129,900 sh (-53.07%)
» More
» Details

Insider Trades

Latest Guru Trades with SPNC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NAS:VASC, NAS:CYNO, NAS:MDXG, NYSE:ITGR, NAS:CSII, NAS:KTWO, NAS:CNMD, OTCPK:IOBCF, NAS:OFIX, NYSE:CRY, NAS:INGN, NAS:BABY, NAS:GNMK, OTCPK:MZRTF, NAS:ARAY, NAS:EXAC, NYSE:IVC, OTCPK:NMRD, OTCPK:IPDQF, NAS:XENT » details
Traded in other countries:SC7.Germany,
The Spectranetics Corp develops, manufactures, markets and distributes single-use medical devices. Its products are used to cross, prepare, and treat arterial blockages in the legs and heart and to remove pacemaker and defibrillator cardiac leads.

The Spectranetics Corp is incorporated under the laws of Delaware and formed in 1984. The Company develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company has two operating segments that are identified on a geographic basis: U.S. Medical and International Medical. U.S. Medical and International Medical offer the same products and services but operate in different geographic regions, have different distribution networks and different regulatory environments. Its products are used to treat arterial blockages in the heart and legs and to remove pacemaker and defibrillator cardiac leads. Approximately 68% of its disposable product revenue is from products used in connection with its proprietary excimer laser system, the CVX-300. Its single-use laser catheters contain up to 250 small diameters, flexible optical fibers that can access difficult to reach peripheral and coronary anatomy and produce evenly distributed laser energy at the tip of the catheter for more uniform ablation. Its disposable products are develops in two categories: Vascular Intervention (VI) and Lead Management (LM). Vascular Intervention products include; support catheters to facilitate crossing of peripheral and coronary arterial blockages, and retrograde access and guidewire retrieval devices used in the treatment of peripheral arterial blockages, including chronic total occlusions, drug delivery catheters for vascular delivery of drugs and diagnostic agents. Lead Management products include: excimer laser sheaths; non-laser sheaths; and cardiac lead management accessories for the removal of pacemaker and defibrillator cardiac leads. Its competitors are manufacturers of products used in competing therapies within the peripheral and coronary atherectomy markets, such as: atherectomy and thrombectomy, using mechanical methods to remove arterial blockages, balloon angioplasty and stents, specialty balloon angioplasty, bypass surgery and amputation. The Company's products are medical devices subject to extensive regulation by the FDA under the Federal Food, Drug, and Cosmetic Act, or FDCA. FDA regulations govern.

Guru Investment Theses on The Spectranetics Corp

Baron Funds Comments on The Spectranetics Corp. - Aug 19, 2015

The Spectranetics Corporation (NASDAQ:SPNC) is a medical device company that specializes in equipment that clears plaque from cardiac and peripheral (arm and leg) arteries. Shares fell after the company reported that it had missed revenues in the first quarter and lowered full year guidance. We believe the market misunderstood certain dynamics and bought more near the bottom. (Randy Gwirtzman)





From Baron Funds’ second quarter 2015 commentary.



Check out Ron Baron latest stock trades

Ratios

vs
industry
vs
history
P/B 11.59
SPNC's P/B is ranked lower than
91% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 3.08 vs. SPNC: 11.59 )
Ranked among companies with meaningful P/B only.
SPNC' s P/B Range Over the Past 10 Years
Min: 0.78  Med: 4.41 Max: 13.07
Current: 11.59
0.78
13.07
P/S 3.60
SPNC's P/S is ranked lower than
58% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 3.02 vs. SPNC: 3.60 )
Ranked among companies with meaningful P/S only.
SPNC' s P/S Range Over the Past 10 Years
Min: 0.69  Med: 3.57 Max: 8.26
Current: 3.6
0.69
8.26
Current Ratio 2.20
SPNC's Current Ratio is ranked lower than
56% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. SPNC: 2.20 )
Ranked among companies with meaningful Current Ratio only.
SPNC' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 2.66 Max: 8.52
Current: 2.2
1.4
8.52
Quick Ratio 1.76
SPNC's Quick Ratio is ranked lower than
51% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 1.82 vs. SPNC: 1.76 )
Ranked among companies with meaningful Quick Ratio only.
SPNC' s Quick Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.31 Max: 7.99
Current: 1.76
1.2
7.99
Days Inventory 144.64
SPNC's Days Inventory is ranked lower than
56% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 134.83 vs. SPNC: 144.64 )
Ranked among companies with meaningful Days Inventory only.
SPNC' s Days Inventory Range Over the Past 10 Years
Min: 82.8  Med: 87.59 Max: 146.27
Current: 144.64
82.8
146.27
Days Sales Outstanding 57.58
SPNC's Days Sales Outstanding is ranked higher than
66% of the 277 Companies
in the Global Medical Devices industry.

( Industry Median: 66.89 vs. SPNC: 57.58 )
Ranked among companies with meaningful Days Sales Outstanding only.
SPNC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.49  Med: 58.06 Max: 73.19
Current: 57.58
48.49
73.19
Days Payable 31.81
SPNC's Days Payable is ranked lower than
76% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 57.49 vs. SPNC: 31.81 )
Ranked among companies with meaningful Days Payable only.
SPNC' s Days Payable Range Over the Past 10 Years
Min: 14.31  Med: 21.02 Max: 241.52
Current: 31.81
14.31
241.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.90
SPNC's 3-Year Average Share Buyback Ratio is ranked lower than
59% of the 209 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. SPNC: -6.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SPNC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.1  Med: -6.9 Max: -1.2
Current: -6.9
-8.1
-1.2

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.01
SPNC's Price/Median PS Value is ranked higher than
52% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 1.02 vs. SPNC: 1.01 )
Ranked among companies with meaningful Price/Median PS Value only.
SPNC' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 0.95 Max: 2.13
Current: 1.01
0.21
2.13
Earnings Yield (Greenblatt) (%) -3.50
SPNC's Earnings Yield (Greenblatt) (%) is ranked lower than
61% of the 315 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. SPNC: -3.50 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SPNC' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -3.5  Med: 0.6 Max: 31.1
Current: -3.5
-3.5
31.1

More Statistics

Revenue (TTM) (Mil) $264.1
EPS (TTM) $ -1.30
Beta1.41
Short Percentage of Float11.23%
52-Week Range $11.09 - 25.81
Shares Outstanding (Mil)43.20

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 270 300 356
EPS ($) -1.08 -0.82 -0.47
EPS w/o NRI ($) -1.08 -0.82 -0.47
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SPNC

Headlines

Articles On GuruFocus.com
Steven Cohen's Point72 Raises Stake in Spectranetics Oct 22 2015 
Baron Funds Comments on The Spectranetics Corp. Aug 19 2015 
Baron Funds Comments on Spectranetics Corporation Feb 26 2014 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 08 2010 
Spectranetics Corp. Reports Operating Results (10-Q) Nov 06 2009 
Spectranetics Corp. Reports Operating Results (10-Q) Aug 10 2009 
Spectranetics Corp. Reports Operating Results (10-Q) May 11 2009 
Weekly CEO Buys Highlight: Spectranetics Corp., Noven Pharmaceuticals Inc., Dolan Media Company, Mod Sep 09 2008 

More From Other Websites
Hedge Funds Are Finally Buying Scientific Games Corp (SGMS) Again Dec 01 2016
Spectranetics Corp (SPNC)Hedge Funds Are Snapping Up Nov 30 2016
ETFs with exposure to The Spectranetics Corp. : November 22, 2016 Nov 22 2016
Spectranetics Receives CE Mark for Stellarex™ 0.014” Drug-Coated Balloon Nov 21 2016
The Spectranetics Corp. breached its 50 day moving average in a Bullish Manner : SPNC-US : November... Nov 21 2016
QT Vascular Announces That The Federal Circuit Denies AngioScore Petition For Rehearing Nov 18 2016
SPECTRANETICS CORP Files SEC form 8-K, Regulation FD Disclosure Nov 14 2016
Spectranetics to Attend Upcoming Investor Conferences Nov 07 2016
SPECTRANETICS CORP Financials Nov 04 2016
ETF’s with exposure to The Spectranetics Corp. : November 2, 2016 Nov 02 2016
SPECTRANETICS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 02 2016
Stellarex™ ILLUMENATE Pivotal Results Are Top-tier in the Most Complex Patient Group Studied in... Nov 02 2016
Spectranetics Files PMA Application for FDA Approval of the Stellarex™ Drug-Coated Balloon Nov 02 2016
SPECTRANETICS CORP Files SEC form 10-Q, Quarterly Report Nov 01 2016
The Spectranetics Corp. :SPNC-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016 Oct 31 2016
Spectranetics gets vote of confidence Oct 31 2016
Edited Transcript of SPNC earnings conference call or presentation 27-Oct-16 8:30pm GMT Oct 28 2016
Spectranetics reports 3Q loss Oct 27 2016
Spectranetics reports 3Q loss Oct 27 2016
Spectranetics Corp Earnings Call scheduled for 4:30 pm ET today Oct 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)